Comparing Common Peptides for Muscle, Fat Loss and Recovery

Not All Peptides Are Created Equal

Walk into any gym locker room, and you'll hear lifters talking about peptides. The problem is, they often talk about them like they're all interchangeable. They aren't. Choosing the right peptide is like choosing the right tool for a job. You wouldn't use a sledgehammer to hang a picture frame, and a pure recovery peptide isn't the obvious pick when your main goal is adding mass.

This is where people waste money and time. They pick a peptide based on hype without understanding its specific mechanism or how it compares to the alternatives. Is Ipamorelin really better than GHRP-6? Is BPC-157 enough, or does TB-500 add anything? As of October 2026, no trial has compared these peptides head-to-head in people, so the comparisons below draw on animal studies, a few small human trials and user reports, labeled as such.

The GH Secretagogue Showdown: Raw Power vs. Precision

First, let's get the classes straight. You have GHS (growth hormone secretagogues), which are also called GHRPs (growth hormone releasing peptides), and you have GHRH (growth hormone releasing hormone) analogs. The GHS/GHRPs create a pulse of GH. The GHRH analogs amplify that pulse. In a 1990 study of 18 healthy men, low IV doses of GHRP-6 given with GHRH released GH synergistically, more than the sum of each alone, which is why users combine the two classes.

The real debate is which GHS to use as the primary driver.

The Old Guard: GHRP-6 & GHRP-2

GHRP-6 is the original compound in this class. It binds to the ghrelin receptor and causes a strong pulse of GH. In the 1990 study, the highest IV dose (1 mcg/kg) also roughly doubled prolactin and cortisol. Users report that it makes them ravenously hungry, often within 15-30 minutes. For a 180-pound hardgainer trying to crack 200, users describe this as a feature, not a bug: the hunger makes it easier to get the calories down for a serious bulk. But for anyone trying to stay lean, GHRP-6 is a messy tool.

GHRP-2 (pralmorelin) is the slightly more refined cousin, and it's approved in Japan only as a single-dose diagnostic test for GH deficiency. Users describe a similarly strong GH pulse but with less of the intense hunger. The catch is cortisol: in a 1998 study in pigs, both GHRP-2 and GHRP-6 raised ACTH and cortisol (neither changed prolactin in that study). Higher cortisol can be catabolic and hinder recovery, which is why many users now pass over GHRP-2 for more selective options.

The Precision Tool: Ipamorelin

This is where things get interesting. Ipamorelin is the most selective GHS in this class. In the 1998 animal study that introduced it, ipamorelin released about as much GH as GHRP-6 in rats and pigs without raising ACTH or cortisol, even at doses more than 200 times its effective dose. Users also report little added hunger. That selectivity is why most users prefer it. The benefits they describe (improved recovery, better sleep quality and enhanced fat metabolism) are self-reported; no trial has measured them.

The human evidence is thinner than its reputation. As of October 2026, ipamorelin isn't approved anywhere. In a Phase 2 trial of 117 adults after abdominal surgery, IV ipamorelin missed its primary endpoint (median time to a first tolerated meal was 25.3 hours versus 32.6 hours on placebo, not statistically significant), and development stopped. The ipamorelin group had more low potassium, insomnia and high blood sugar, and 2 deaths after treatment ended (causality unclear). In October 2024, FDA's compounding advisory committee voted 0-12, with one abstention, against adding it to the 503A bulks list. Users report water retention, tingling hands, headaches and drowsiness, so its clean profile is relative, not side-effect-free.

The Amplifier: CJC-1295 (without DAC)

CJC-1295 without DAC (often sold as Mod GRF 1-29) is the standard GHRH analog users stack with a GHS. Users describe a modest effect on its own. Its job is to bind to the GHRH receptor and amplify the pulse the GHS creates. Community guides put the saturation dose (the point of diminishing returns) at around 100mcg and call 100mcg of CJC-1295 with 100mcg of a GHS the standard protocol; we couldn't trace either figure to a published dose-response study. The longer-acting version with DAC behaves differently: in 2006 trials in healthy adults, a single injection kept GH raised for 6 days or more.

So, Which GH Stack Wins?

In user reports, it comes down to the primary goal. None of these protocols has been tested in a trial; the doses are user and vendor figures, not recommendations.

In user reports, the Ipamorelin and CJC-1295 combination is the most common choice because it has fewer reported side effects; no trial has shown it works better. Our article on peptide cycling strategies covers how long users run it.

The Recovery Specialists: Fixing What You Break

Switching gears completely, recovery peptides are what users turn to when something hurts. They aren't used for systemic GH pulses; users take them for targeted tissue repair. The two big players here are BPC-157 and TB-500.

BPC-157: The Tendon & Gut Fixer

BPC-157, a fragment of a body protection compound found in gastric juice, is the most discussed peptide for connective tissue repair. The data are almost entirely preclinical: a 2025 systematic review found 35 animal or cell studies, one small human case series and no clinical safety data. But the animal evidence is consistent: in rodents it sped the healing of tendons, ligaments, and muscle. Its primary mechanism appears to be promoting angiogenesis (the creation of new blood vessels) via upregulation of vascular endothelial growth factor (VEGF). More blood flow to a poorly vascularized tissue like a tendon could help recovery, but that hasn't been measured in people.

Rodent data suggest it's stable in stomach acid, which is why some users take oral forms for gut health issues. For a nagging lifter's elbow or patellar tendonitis, a subcutaneous injection near the site is the community standard, though no human trial has compared injection sites. As of October 2026, BPC-157 isn't approved anywhere, and WADA's 2026 Prohibited List names it under S0.

TB-500: The Systemic Mobility Agent

TB-500 is often called the synthetic version of thymosin beta-4, but doping-control chemists identified it as Ac-LKKTETQ, a 7-amino-acid fragment (residues 17-23) of that 43-amino-acid protein. Full thymosin beta-4 plays a big role in cell migration and differentiation. Its main claim to fame is binding a protein called actin, which is a fundamental building block of cell structure and movement. In lab and animal studies, this translates to reduced inflammation and improved cell migration to wound sites. Human trials have tested the full protein, not the fragment, and as of October 2026 FDA says it has found no human exposure data for TB-500. Lifters often report feeling less sore and more flexible on it, but no study has measured that. WADA's 2026 list prohibits thymosin beta-4 and its derivatives, naming TB-500, under S2.3.

The Synergy: Using Both for Major Repairs

People stack them because they're thought to attack the problem from different angles.

• BPC-157 works directly on the injury site in rodent studies, building new blood vessels and laying down the groundwork for repair.
• TB-500 is used as a systemic agent, based on full thymosin beta-4 data showing reduced inflammation and better movement of repair cells to the area.

For a serious injury, like a partial muscle tear or chronic tendinopathy that just won't heal, running them together is a common community approach. As of October 2026, though, no controlled study has tested the combination, so the synergy is a mechanistic idea rather than a demonstrated result.

What we still don't know

Without head-to-head trials, any ranking rests on mechanism, animal data and user preference. For a healthy lifter looking for an edge in body composition, the Ipamorelin + CJC-1295 stack is the one users most often describe, but no trial has measured muscle gain or fat loss for any GH secretagogue. For a nagging joint or tendon, BPC-157 is the first peptide most users research. Its track record in animal models is consistent, but the human data are small uncontrolled pilots, and a University of Arkansas Phase 1 trial after rotator cuff repair (NCT07803250) isn't set to start until January 2027. The TB-500 fragment has no human data at all.

Regulation is unsettled too. FDA's compounding advisory committee reviewed BPC-157 and TB-500 in July 2026, but as of October 2026 FDA hasn't announced a decision; our article on the legal implications of peptide use covers what that means. For what years of use might do to your endocrine system, see long-term effects of peptide use.

Comparison table